On­colyt­ic virus start­up Ca­li­di se­cures $25M to­ward Se­ries B round

Ca­li­di Bio­ther­a­peu­tics, a San Diego biotech work­ing on de­vel­op­ing al­lo­gene­ic cell de­liv­ery of on­colyt­ic virus­es, said Fri­day that in­vestors have com­mit­ted $25 mil­lion to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER